🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 31/08/2004 | 9,66 | 9,85 | 9,30 | 9,73 | +0,62% | 5,69% | 493.200 |
| 30/08/2004 | 9,89 | 9,92 | 9,51 | 9,67 | -2,91% | 4,15% | 271.800 |
| 27/08/2004 | 9,75 | 10,05 | 9,69 | 9,96 | +2,05% | 3,69% | 296.200 |
| 26/08/2004 | 10,02 | 10,04 | 9,76 | 9,76 | -2,40% | 2,79% | 225.000 |
| 25/08/2004 | 9,77 | 10,00 | 9,60 | 10,00 | +2,99% | 4,09% | 379.500 |
| 24/08/2004 | 9,91 | 10,04 | 9,64 | 9,71 | -1,12% | 4,04% | 304.000 |
| 23/08/2004 | 9,94 | 10,17 | 9,80 | 9,82 | -1,21% | 3,72% | 746.400 |
| 20/08/2004 | 9,46 | 9,94 | 9,26 | 9,94 | +5,74% | 7,19% | 513.100 |
| 19/08/2004 | 9,40 | 9,55 | 9,24 | 9,40 | -0,53% | 3,30% | 405.800 |
| 18/08/2004 | 8,97 | 9,58 | 8,95 | 9,45 | +5,00% | 7,02% | 618.800 |
| 17/08/2004 | 9,25 | 9,40 | 8,93 | 9,00 | -2,81% | 5,08% | 936.000 |
| 16/08/2004 | 8,56 | 9,48 | 8,56 | 9,26 | +7,80% | 10,75% | 527.400 |
| 13/08/2004 | 8,75 | 8,85 | 8,46 | 8,59 | -2,39% | 4,46% | 307.100 |
| 12/08/2004 | 8,76 | 8,84 | 8,35 | 8,80 | -0,45% | 5,59% | 473.200 |
| 11/08/2004 | 8,52 | 8,91 | 8,22 | 8,84 | +3,88% | 8,10% | 613.400 |
| 10/08/2004 | 8,20 | 8,51 | 8,06 | 8,51 | +4,16% | 5,49% | 416.000 |
| 09/08/2004 | 8,35 | 8,47 | 8,09 | 8,17 | -2,39% | 4,55% | 439.000 |
| 06/08/2004 | 8,50 | 8,54 | 8,30 | 8,37 | -2,67% | 2,82% | 529.800 |
| 05/08/2004 | 8,95 | 9,01 | 8,55 | 8,60 | -4,55% | 5,14% | 338.200 |
| 04/08/2004 | 8,70 | 9,10 | 8,63 | 9,01 | +2,39% | 5,40% | 422.600 |
| 03/08/2004 | 8,83 | 9,02 | 8,75 | 8,80 | -1,23% | 3,06% | 574.400 |
| 02/08/2004 | 9,14 | 9,19 | 8,84 | 8,91 | -3,47% | 3,83% | 637.500 |
| 30/07/2004 | 9,22 | 9,49 | 9,13 | 9,23 | -0,11% | 3,90% | 439.000 |
| 29/07/2004 | 9,26 | 9,48 | 9,08 | 9,24 | -0,11% | 4,32% | 515.300 |
| 28/07/2004 | 9,30 | 9,49 | 9,05 | 9,25 | -1,60% | 4,73% | 574.700 |
| 27/07/2004 | 9,30 | 9,95 | 9,17 | 9,40 | +4,44% | 8,39% | 762.600 |
| 26/07/2004 | 9,05 | 9,14 | 8,88 | 9,00 | +0,00% | 2,87% | 546.100 |
| 23/07/2004 | 9,19 | 9,32 | 9,00 | 9,00 | -2,91% | 3,48% | 456.200 |
| 22/07/2004 | 9,01 | 9,58 | 8,94 | 9,27 | +2,89% | 7,10% | 1.205.700 |
| 21/07/2004 | 10,03 | 10,08 | 9,00 | 9,01 | -10,44% | 10,77% | 844.400 |